The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunin D.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Bagmanyan S.D.

Pirogov Russian National Research Medical University

Pogorova A.R.

Pirogov Russian National Research Medical University

Restless legs syndrome

Authors:

Katunina E.A., Titova N.V., Katunin D.A., Bagmanyan S.D., Pogorova A.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(2): 106‑113

DOI: 10.17116/jnevro2021121021106

Read: 15677 times

Contact the author
Table of contents

RESTLESS LEGS SYNDROME
RESTLESS LEGS SYNDROME

To cite this article:

Katunina EA, Titova NV, Katunin DA, Bagmanyan SD, Pogorova AR. Restless legs syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(2):106‑113. (In Russ.)
https://doi.org/10.17116/jnevro2021121021106

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Portopulmonary hype­rtension. Journal of Respiratory Medi­cine. 2025;(2):39-44
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Rapi­dly progressive periodontitis. (A successful expe­rience of eighteen years of obse­rvation). Russian Journal of Stomatology. 2025;(2):61-67
Bacterial vagi­nosis: modern views. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):261-268
Comparative analysis of microtextured breast implant shells. Plastic Surgery and Aesthetic Medi­cine. 2025;(2-2):13-15
Method of photodynamic action in surgical treatment of local limi­ted peri­tonitis in the expe­riment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86
Abstract:

Restless legs syndrome (RLS) is seen widely in clinical practice. RLS commonly occurs at night time and presents with unpleasant or uncomfortable sensations in the legs that causes an urge to move them. This article describes the epidemiology, risk factors and pathophysiology of RLS. There is a detailed description of clinical presentations, diagnostic criteria and also management of RLS.

Keywords:

restless legs syndrome
pathogenesis
clinical presentation
treatment
augmentation

Authors:

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunin D.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Bagmanyan S.D.

Pirogov Russian National Research Medical University

Pogorova A.R.

Pirogov Russian National Research Medical University

Received:

31.05.2020

Accepted:

03.06.2020

Close metadata

References:

  1. Leclair-Visionneau L, Vecchierini MF, Schroder C, Charley Monaca C. French Consensus: How to diagnose restless legs syndrome. Rev Neurol (Paris). 2018;174(7-8):508–514.  https://doi.org/10.1016/j.neurol.2018.08.003
  2. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873.  https://doi.org/10.1016/j.sleep.2014.03.025
  3. Allen RP, Walters AS, Montplaisir J, at al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286–1292. https://doi.org/10.1001/archinte.165.11.1286
  4. Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283–295.  https://doi.org/10.1016/j.smrv.2011.05.002
  5. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome:diagnostic criteria, special considerations and epidemiology. Sleep Med. 2003;4(2):101–119.  https://doi.org/10.1016/S1389-9457(03)00010-8
  6. Chen NH, Chuang LP, Yang CT, et al. The prevalence of restless legs syndrome in Taiwanese adults. Psychiatry Clin Neurosci. 2010;64(2):170–178.  https://doi.org/10.1111/j.1440-1819.2010.02067.x
  7. Shi Y, Yu H, Ding D, et al. Prevalence and risk factors of restless legs syndrome among Chinese adults in a rural community of Shanghai in China. PLoS One. 2015;10(3):e0121215. https://doi.org/10.1371/journal.pone.0121215
  8. Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med. 2010;11(9):807–815.  https://doi.org/10.1016/j.sleep.2010.07.007
  9. Buchfuhrer MJ. Restless legs syndrome (RLS) with expansion of symptoms to the face. Sleep Med. 2008;9(2):188–190.  https://doi.org/10.1016/j.sleep.2007.02.013
  10. Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med. 2010;11(1):31–37.  https://doi.org/10.1016/j.sleep.2009.03.007
  11. Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164(2):196–202.  https://doi.org/10.1001/archinte.164.2.196
  12. Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents -- the Peds REST study. Pediatrics. 2007;120(2):253–266.  https://doi.org/10.1542/peds.2006-2767
  13. Zhang J, Lam SP, Li SX, et al. Restless legs symptoms in adolescents: epidemiology, heritability, and pubertal effects. J Psychosom Res. 2014;76(2):158–164.  https://doi.org/10.1016/j.jpsychores.2013.11.017
  14. Cesnik E, Casetta I, Turri M, et al. Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. Neurology. 2010;75(23):2117–2120. https://doi.org/10.1212/WNL.0b013e318200d779
  15. Winkelmann J, Polo O, Provini F, et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord. 2007;22:449–458.  https://doi.org/10.1002/mds.21587
  16. Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med. 2002;3:3–7.  https://doi.org/10.1016/S1389-9457(02)00140-5
  17. Xiong L, Jang K, Montplaisir J, et al. Canadian restless legs syndrome twin study. Neurology. 2007;68(19):1631–1633. https://doi.org/10.1212/01.wnl.0000261016.90374.fd
  18. Stiasny-Kolster K, Moller JC, Zschocke J, et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord. 2004;19(2):192–196.  https://doi.org/10.1002/mds.10631
  19. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med. 2009;10(1):123–128.  https://doi.org/10.1016/j.sleep.2007.11.012
  20. Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009;132:2403–2412. https://doi.org/10.1093/brain/awp125
  21. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61(3):304–309.  https://doi.org/10.1212/01.WNL.0000078887.16593.12
  22. Earley CJ, Kuwabara H, Wong DF, et al. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep. 2011;34(3):341–347.  https://doi.org/10.1093/sleep/34.3.341
  23. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord. 2000;15(1):154–158. https://doi.org/10.1002/1531-8257(200001)15:1<154::aid-mds1025>3.0.co;2-q "> 3.0.co;2-q" target="_blank">https://doi.org/10.1002/1531-8257(200001)15:1<154::aid-mds1025>3.0.co;2-q
  24. Zhao H, Zhu W, Pan T, et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res. 2007;85(5):1065–1076. https://doi.org/10.1002/jnr.21207
  25. Trenkwalder C, Zieglgansberger W, Ahmedzai SH, Hogl B. Pain, opioids, and sleep: implications for restless legs syndrome treatment. Sleep Med. 2017;31:78–85.  https://doi.org/10.1016/j.sleep.2016.09.017
  26. Ferre S, Earley C, Gulyani S, Garcia-Borreguero D. In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Med. 2017;31:86–92.  https://doi.org/10.1016/j.sleep.2016.08.019
  27. Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59(4):639–641.  https://doi.org/10.1212/WNL.59.4.639
  28. Allen RP, Barker PB, Wehrl FW, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56(2):263–265.  https://doi.org/10.1212/WNL.56.2.263
  29. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004;62(9):1563–1567. https://doi.org/10.1212/01.wnl.0000123251.60485.ac
  30. Dauvilliers Y, Winkelmann J. Restless legs syndrome: update on pathogenesis. Curr Opin Pulm Med. 2013;19(6):594-600.  https://doi.org/10.1097/mcp.0b013e328365ab07
  31. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18(2):128–147.  https://doi.org/10.1097/00004691-200103000-00004
  32. Dzaja A, Wehrle R, Lancel M, Pollmacher T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep. 2009;32(2):169–174.  https://doi.org/10.1093/sleep/32.2.169
  33. Karroum EG, Golmard J-L, Leu-Semenescu S, Arnulf I. Sensations in restless legs syndrome. Sleep Med. 2012;13(4):402–408.  https://doi.org/10.1016/j.sleep.2011.01.021
  34. Karroum EG, Leu-Semenescu S, Arnulf I. Topography of the sensations in primary restless legs syndrome. J Neurol Sci. 2012;320(1–2):26–31.  https://doi.org/10.1016/j.jns.2012.05.051
  35. Cho YW, Song ML, Earley CJ, Allen RP. Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. Sleep Med. 2015;16(6):775–778.  https://doi.org/10.1016/j.sleep.2014.12.024
  36. Koo YS, Lee G-T, Lee SY, et al. Topography of sensory symptoms in patients with drug-naïve restless legs syndrome. Sleep Med. 2013;14(12):1369–1374. https://doi.org/10.1016/j.sleep.2013.09.006
  37. Montplaisir J, Boucher S, Nicolas A, et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord. 1998;13(2):324–329.  https://doi.org/10.1002/mds.870130220
  38. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61–65.  https://doi.org/10.1002/mds.870120111
  39. Ferri R, Fulda S, Allen RP, et al. World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med. 2016;26:86–95.  https://doi.org/10.1016/j.sleep.2016.10.010
  40. Ferri R, Rundo F, Zucconi M, et al. Diagnostic accuracy of the standard and alternative periodic leg movement during sleep indices for restless legs syndrome. Sleep Med. 2016;22:97–99.  https://doi.org/10.1016/j.sleep.2015.11.018
  41. Trenkwalder C, Hening WA, Walters AS, et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999;14(1):102–110. https://doi.org/10.1002/1531-8257(199901)14:1<102::AID-MDS1017>3.0.CO;2-E "> 3.0.CO;2-E" target="_blank">https://doi.org/10.1002/1531-8257(199901)14:1<102::AID-MDS1017>3.0.CO;2-E
  42. Haba-Rubio J, Marti-Soler H, Marques-Vidal P, et al. Prevalence and determinants of periodic limb movements in the general population: PLMS in the general population. Ann Neurol. 2016;79:464–474.  https://doi.org/10.1016/S2213-2600(15)00043-0
  43. Fantini ML, Michaud M, Gosselin N, et al. Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activation. Neurology. 2002;59(12):1889–1894. https://doi.org/10.1212/01.WNL.0000038348.94399.F6
  44. Ferri R, Zucconi M, Rundo F, et al. Heart rate and spectral EEG changes accompanying periodic and non-periodic leg movements during sleep. Clin Neurophysiol. 2007;118(2):438–448.  https://doi.org/10.1016/j.clinph.2006.10.007
  45. Sforza E, Pichot V, Cervena K, et al. Cardiac variability and heart-rate increment as a marker of sleep fragmentation in patients with a sleep disorder: a preliminary study. Sleep. 2007;30(1):43–51.  https://doi.org/10.1093/sleep/30.1.43
  46. Pennestri MH, Montplaisir J, Colombo R, et al. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology. 2007;68(15):1213–1218. https://doi.org/10.1212/01.wnl.0000259036.89411.52
  47. Walters AS, Rye DB. Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke. Sleep. 2009;32(5):589–597.  https://doi.org/10.1093/sleep/32.5.589
  48. Siddiqui F, Strus J, Ming X, et al. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol. 2007;118(9):1923–1930. https://doi.org/10.1016/j.clinph.2007.05.006
  49. Cosentino FI, Arico D, Lanuzza B, et al. Absence of cardiovascular disease risk factors in restless legs syndrome. Acta Neurol Scand. 2012;125(5):319–325.  https://doi.org/10.1111/j.1600-0404.2011.01563.x
  50. Trenkwalder C, Allen R, Hogl B, et al. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86(14):1336–1343. https://doi.org/10.1212/WNL.0000000000002542
  51. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of Restless Legs Syndrome in a primary care population: REST (RLS epidemiology, symptoms and treatment) primary care study. Sleep Med. 2004;5(3):237–246.  https://doi.org/10.1016/j.sleep.2004.03.006
  52. Crochard A, El Hasnaoui A, Pouchain D, et al. Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study. Mov Disord. 2007;22(6):791–797.  https://doi.org/10.1002/mds.21325
  53. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873.  https://doi.org/10.1016/j.sleep.2014.03.025
  54. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med. 2000;1:11–19.  https://doi.org/10.1016/s1389-9457(99)00012-x
  55. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47(6):1435–1441. https://doi.org/10.1212/WNL.47.6.1435
  56. Bachmann CG, Rolke R, Scheidt U, et al. Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome. Brain. 2010;133(3):762–770.  https://doi.org/10.1093/brain/awq026
  57. Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep. 2007;30(7):866–871.  https://doi.org/10.1093/sleep/30.7.866
  58. Allen RP. Contraversies and challenges in defining etiology and pathophysiology of restless legs syndrome. Am J Med. 2007;120(1 Suppl 1):S13–21.  https://doi.org/10.1016/j.amjmed.2006.11.003
  59. Chokroverty S. Differential diagnoses of restless legs syndrome/Willis-Ekbom disease: mimics and comorbidities. Sleep Med Clin. 2015;10(3):249–262.  https://doi.org/10.1016/j.jsmc.2015.05.001
  60. Leschziner G, Gringras P. Restless Legs Syndrome. BMJ. 2012;334:e3056. https://doi.org/10.1136/bmj.e3056
  61. Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med. 2016;25:16–23.  https://doi.org/10.1016/j.sleep.2016.06.021
  62. Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906–913.  https://doi.org/10.1016/j.sleep.2011.06.009
  63. Szentkiralyi A, Fendrich K, Hoffmann W, et al. Incidence of restless legs syndrome in two population-based cohort studies in Germany. Sleep Med. 2011;12(9):815–820.  https://doi.org/10.1016/j.sleep.2011.06.016
  64. Kagimura T, Nomura T, Kusumi M, et al. Prospective survey on the natural course of restless legs syndrome over two years in a closed cohort. Sleep Med. 2011;12(9):821–826.  https://doi.org/10.1016/j.sleep.2011.04.012
  65. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131(4):902–917.  https://doi.org/10.1093/brain/awm244
  66. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17–27.  https://doi.org/10.4065/81.1.17
  67. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27(5):907–914.  https://doi.org/10.1093/sleep/27.5.907
  68. Limousin N, Flamand M, Schroder C, Monaca CC. French Consensus: Treatment of Newly Diagnosed Restless Legs Syndrome. Rev Neurol. 2018;174(7–8):515–521.  https://doi.org/10.1016/j.neurol.2018.06.002
  69. Leu-Semenescu S, Petiau C, Charley Monaca C, Dauvilliers Y. French consensus: Augmentation syndrome in restless legs syndrome. Rev Neurol (Paris). 2018;174(7–8):532–539.  https://doi.org/10.1016/j.neurol.2018.06.004
  70. Garcia-Borreguero D, Cano-Pumarega I. New Concepts in the Management of Restless Legs Syndrome. BMJ. 2017;356:j104. https://doi.org/10.1136/bmj.j104
  71. Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.  https://doi.org/10.1186/1471-2377-11-117
  72. Bogan RK, Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85(6):512–521.  https://doi.org/10.4065/mcp.2009.0700
  73. Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebocontrolled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35(4):165–173.  https://doi.org/10.1097/wnf.0b013e318259eac8
  74. Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–292.  https://doi.org/10.5664/JCSM.1074
  75. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(6):311–320.  https://doi.org/10.1097/wnf.0b013e3181b3ab16
  76. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32(2):159–168.  https://doi.org/10.1093/sleep/32.2.159
  77. Kushida CA, Becker PM, Ellenbogen AL, C et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439–446.  https://doi.org/10.1212/01.wnl.0000341770.91926.cc
  78. Inoue Y, Hirata K, Uchimura N, et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29(1):13–21.  https://doi.org/10.1185/03007995.2012.746217
  79. Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47(3):269–277.  https://doi.org/10.3109/07853890.2015.1025825
  80. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.  https://doi.org/10.1016/j.sleep.2016.01.017
  81. Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635–643.  https://doi.org/10.5665/sleep.3558
  82. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–213.  https://doi.org/10.1093/sleep/19.3.205
  83. Mitterling T, Frauscher B, Falkenstetter T, et al. Is there a polysomnographic signature of augmentation in restless legs syndrome? Sleep Med. 2014;15(10):1231–1240. https://doi.org/10.1016/j.sleep.2014.05.023
  84. Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621–631.  https://doi.org/10.1056/nejmoa1303646
  85. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12(5):431–439.  https://doi.org/10.1016/j.sleep.2011.03.003
  86. Hogl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12(4):351–360.  https://doi.org/10.1016/j.sleep.2010.12.007
  87. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002;3(Suppl):S23–25.  https://doi.org/10.1016/S1389-9457(02)00144-2
  88. Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280–1285. https://doi.org/10.1016/j.sleep.2012.08.004
  89. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12(5):440–444.  https://doi.org/10.1016/j.sleep.2010.11.002
  90. Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(2):e2504. https://doi.org/10.1097/md.0000000000002504
  91. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9(5):572–574.  https://doi.org/10.1016/j.sleep.2007.07.020
  92. Garcia-Borreguero D, Silber MH, Winkelman JW, H et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.  https://doi.org/10.1016/j.sleep.2016.01.017
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.